-GlcNAcylation regulates OTX2's proteostasis.

-GlcNAcylation is a key post-translational modification, playing a vital role in cell signaling during development, especially in the brain. In this study, we investigated the role of -GlcNAcylation in regulating the homeobox protein OTX2, which contributes to various brain disorders, such as combined pituitary hormone deficiency, retinopathy, and medulloblastoma. Our research demonstrated that, under normal physiological conditions, the proteasome plays a pivotal role in breaking down endogenous OTX2.

Recurrence of Guttae and Endothelial Dysfunction After Successful Descemet Stripping Only in Fuchs Dystrophy.

Purpose: There are limited data about long-term durability of endothelial rejuvenation after Descemet stripping only (DSO). This study reports a case of bilaterally recurrent endothelial dysfunction and guttae formation after initially successful DSO in combination with cataract extraction (DSO-CE).

Methods: This is a retrospective case report.

Socioeconomic Disparities in the Prevalence of Cardiometabolic Risk Factors in Ghanaian Women.

Background: Recent trends toward urbanization in developing countries like Ghana, coupled with nutritional transition and aging populations, have led to a rapid increase in the prevalence of noncommunicable diseases such as obesity, diabetes, and hypertension. The purpose of this study was to evaluate the association between socioeconomic status and cardiometabolic risk factors among women in Ghana.

Methods: Data for this analysis were obtained from Wave 1 of the Ghana Study of Global Aging and Health, conducted in 2007, and included women 18 years and older.

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

Sphingosine kinase 2 (Sphk2) has an oncogenic role in cancer. A recently developed first-in-class Sphk2 specific inhibitor ABC294640 displays antitumor activity in many cancer models. However, the role of Sphk2 and the antitumor activity of its inhibitor ABC294640 are not known in cholangiocarcinoma.